A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

PURPOSE: Maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were assessed in this phase 1 study of PNT2258, a BCL-2-targeted liposomal formulation of a 24-base DNA oligonucleotide called PNT100. METHODS: Patients with malignant solid tumors were assigned sequentially to one of te...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Tolcher, Anthony W., Rodrigueza, Wendi V., Rasco, Drew W., Patnaik, Amita, Papadopoulos, Kyriakos P., Amaya, Alex, Moore, Timothy D., Gaylor, Shari K., Bisgaier, Charles L., Sooch, Mina P., Woolliscroft, Michael J., Messmann, Richard A.
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2013
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3909249/
https://ncbi.nlm.nih.gov/pubmed/24297683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2361-0
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki